TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6357269
Drug: Stilboestrol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stilboestrol therapy
Study: 17311979
Drug: Probiotics (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (various strains including Lactobacillus rhamnosus GG, L. reuteri, L. casei, L. acidophilus, Escherichia coli strain Nissle 1917, certain bifidobacteria, Enterococcus faecium SF68, Saccharomyces boulardii)
Study: 15081569
Drug: ximelagatran 30
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ximelagatran 30 mg
Study: 15081569
Drug: ximelagatran 60
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ximelagatran 60 mg
Study: 9291
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg/day
Study: 4364175
Drug: Isoprinosine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprinosine (6 g daily for 7 days)
Study: 25023847
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate formulation A (2g)
Study: 25023847
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate formulation B (2g)
Study: 16508278
Drug: 150 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mmol/l calcium lactate prerinse
Study: 16508278
Drug: 30 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mmol/l calcium lactate prerinse
Study: 16508278
Drug: 300 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mmol/l calcium lactate prerinse
Study: 12861344
Drug: 10% Pentastarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Pentastarch infusion (500 ml)
Study: 12861344
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (60 ml) placebo infusion
Study: 11060526
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin G (IVIgG), 1 g/kg body weight, given on days 0, 3, 7, 14, and 21
Study: 11060526
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (comparison group with IgG levels >4 g/L)
Study: 29725191
Drug: SISTAS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SISTAS intervention (12 weekly classes followed by nine monthly booster sessions)
Study: 22673035
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (n=17), 12 sessions of 40 minutes each, three days/week for four weeks.
Study: 16241919
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment and regular monitoring (Group B)
Study: 12362930
Drug: Quinine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (10 mg/kg body weight, intravenous infusion)
Study: 7587918
Drug: Multiple insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple insulin injection treatment (MIT) group
Study: 7587918
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin injection treatment (CIT) group
Study: 1971955
Drug: 15 or
Normalized name: Oseni 25/15 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 or 30 mg flurazepam
Study: 1971955
Drug: 0.25 or
Normalized name: Renese-R 2/0.25 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 or 0.50 mg triazolam
Study: 922640
Drug: No-feedback or
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-feedback or no-treatment
Study: 30879734
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of supplemental parenteral nutrition (PN) after one week
Study: 30879734
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of supplemental parenteral nutrition (PN) within 24 hours
Study: 27964826
Drug: UC-MSC treatment
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSC treatment (1.0 × 10^6 MSCs per kg body weight, six doses through peripheral intravenous infusion)
Study: 21771279
Drug: Internet-based psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based psychological treatment program (Revive) consisting of communication skills training, sensate focus exercises, and regular contact with a therapist
Study: 16534755
Drug: Gd-DTPA-DeA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gd-DTPA-DeA (all doses)
Study: 14635462
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a grass extract (ALK‐Abellò)
Study: 8957141
Drug: Enhanced day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced day treatment program plus abstinent contingent work therapy and housing (EC)
Study: 1568426
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg quinapril (single dose)
Study: 1568426
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg quinapril twice daily for 14 days
Study: 3894337
Drug: Molindone (injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molindone (injection for 2-3 days, then oral for up to 4 weeks)
Study: 3894337
Drug: Haloperidol (injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (injection for 2-3 days, then oral for up to 4 weeks)
Study: 3894337
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Molindone and Haloperidol)
Study: 30268156
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell intradermal vaccinations (two courses of four daily doses)
Study: 27352491
Drug: Oblique insertion
Normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oblique insertion therapy at anatomical points
Study: 24212124
Drug: 3‐month exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐month exercise intervention (160 min·wk of moderate‐intensity aerobic walking, twice weekly resistance training with resistance bands)
Study: 22950925
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (exposed to video, audio, and print advertisements promoting parent-child communication about delaying sexual activity)
Study: 22950925
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not exposed to the treatment messages)
Study: 20230859
Drug: Glucose administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose administration (dose not specified)
Study: 20230859
Drug: Glucose administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose administration (regardless of dose or dual-task conditions)
Study: 8466238
Drug: Nebulised budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised budesonide suspension
Study: 30695078
Drug: Mobile phone
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile phone app providing ACH antibiotic guidelines
Study: 24216616
Drug: fampridine-SR 25
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fampridine-SR 25 mg twice daily
Study: 21882176
Drug: Acitretin 25
Normalized name: acitretin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin 25 mg orally 5 days per week
Study: 9184881
Drug: Emergency medical
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency medical therapy (intravenous vasopressin and esophageal balloon tamponade) followed by elective portacaval shunt in survivors (22 patients)
Study: 9184881
Drug: Emergency medical
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency medical therapy and elective shunt
Study: 7682261
Drug: Aspirin 60-80
Normalized name: aspirin 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 60-80 mg/kg alone (Group A)
Study: 7682261
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus intravenous gamma globulin (IVGG) 400 mg/kg for 5 days (Group B)
Study: 7682261
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus a single dose of IVGG 2.0 gm/kg (Group C)
Study: 22551107
Drug: EDP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP plus mitotane (second-line therapy)
Study: 22551107
Drug: Streptozocin plus
Normalized name: Streptozocin
DrugBank: Streptozocin (DB00428)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Streptozocin plus mitotane (second-line therapy)
Study: 22551107
Drug: EDP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP plus mitotane (first-line therapy, no second-line therapy)
Study: 22551107
Drug: Streptozocin plus
Normalized name: Streptozocin
DrugBank: Streptozocin (DB00428)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Streptozocin plus mitotane (first-line therapy, no second-line therapy)
Study: 18245143
Drug: Weekly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly telephone support (control)
Study: 9890407
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg nicorandil
Study: 9890407
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg nitroglycerin
Study: 1804576
Drug: Pirenzepine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (50 mg b.i.d. perorally)
Study: 26894591
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg/kg (Group-2)
Study: 26894591
Drug: Sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4 mg/kg (Group-4)
Study: 26894591
Drug: Sugammadex 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 16 mg/kg (Group-16)
Study: 11083260
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with DMARDs (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Study: 11083260
Drug: Single DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single DMARD therapy with or without prednisolone
Study: 11083260
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with DMARDs
Study: 9122365
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg thiamine daily for 2 months
Study: 8452112
Drug: Fast neutron
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast neutron radiation (mixed-beam treatment schedule)
Study: 30096702
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus cisplatin (SP): S‐1 40 mg/m2 for 21 days plus cisplatin 60 mg/m2 (q5w)
Study: 30096702
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus cisplatin (XP): capecitabine 1000 mg/m2 for 14 days plus cisplatin 80 mg/m2 (q3w)
Study: 25730028
Drug: IMRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT plus DC-CIK immunotherapy (study group, N = 34)
Study: 25730028
Drug: IMRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT plus DC-CIK immunotherapy (study group)
Study: 21594659
Drug: 150 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 µg clonidine
Study: 18833168
Drug: Proflusak (fluoxetine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proflusak (fluoxetine)
Study: 14959468
Drug: Nifedipin‐retard (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipin‐retard (40 mg/day, 20 mg twice a day)
Study: 14959468
Drug: Nifedipin‐retard (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipin‐retard (20 mg/day) in combination with metoprolol (100 mg/day, 50 mg twice a day)
Study: 16913498
Drug: Dan Shao
Normalized name: Dan shen suan b
DrugBank: Salvianolic acid B (DB19313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dan Shao Tang (DST) and western medicine
Study: 8025366
Drug: Balanced amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced amino acid solution (2510 kJ/24 h) for 6 h
Study: 8025366
Drug: BCAA-enriched solution
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA-enriched solution (2510 kJ/24 h) for 6 h
Study: 8025366
Drug: Balanced amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced amino acid solution (2510 kJ/24 h) for 6 h in healthy volunteers
Study: 8025366
Drug: BCAA-enriched solution
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA-enriched solution (2510 kJ/24 h) for 6 h in healthy volunteers
Study: 22115823
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 5 mg
Study: 25391616
Drug: Treatment-focused genetic
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-focused genetic testing (TFGT)
Study: 19499960
Drug: olmesartan/amlodipine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan/amlodipine 20 mg/5 mg
Study: 19499960
Drug: olmesartan/amlodipine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan/amlodipine 20 mg/10 mg
Study: 9506856
Drug: 25 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg T4 daily for two months (Group C)
Study: 9506856
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg T4 daily for two months (Group D)
Study: 9506856
Drug: 25 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg T4 daily for two months (Group A)
Study: 9506856
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg T4 daily for two months (Group B)
Study: 9506856
Drug: Thyroxine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine administration in group D (ThAab negative)
Study: 24895144
Drug: Fostamatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib (100 mg bid)
Study: 21562819
Drug: Leucine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucine (250 mg/kg bm)
Study: 20617176
Drug: On-treatment CD4+
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment CD4+ T-cell counts
Study: 20617176
Drug: On-treatment HIV
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment HIV RNA levels
Study: 12540386
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (4 g/d, consisting of 45% eicosapentaenoic acid and 39% docosahexaenoic acid as ethyl esters)
Study: 12540386
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (4 g/d)
Study: 12540386
Drug: Placebo (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corn oil, 4 g/d)
Study: 1856147
Drug: Amikacin given
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin given once daily (od)
Study: 1856147
Drug: Amikacin given
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin given twice daily (bd)
Study: 24481679
Drug: Doxorubicin (single-agent)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (single-agent)
Study: 18317369
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (6 mg.kg body weight)
Study: 11788381
Drug: L-Carnitine L-tartrate
Normalized name: L-carnitine (free form) (as L-carnitine L-tartrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine L-tartrate (2 g L-carnitine/day)
Study: 8835550
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with auranofin within one year of diagnosis of RA.
Study: 8835550
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with slow acting antirheumatic drugs (SAARD) after 8 months compared to the early treatment group.
Study: 7280753
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg) administered intramuscularly before repeat BTM and gamma camera studies
Study: 7280753
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered before gamma camera studies
Study: 21804414
Drug: Incisional negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional negative pressure wound therapy (NPWT) applied to closed surgical incisions (Group B)
Study: 3699692
Drug: Euhydration (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euhydration (water intake of 20 ml/kg body weight)
Study: 30832713
Drug: Jin's three-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin's three-needle acupuncture (JTN) treatment
Study: 30832713
Drug: JTN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTN treatment
Study: 26965764
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (700 IU daily)
Study: 21778259
Drug: Formoterol-budesonide combined
Normalized name: budesonide / formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol-budesonide combined treatment (18/640 μg daily)
Study: 21778259
Drug: High-dose budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose budesonide treatment (1,600 μg daily)
Study: 19747781
Drug: High-dose cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide, cisplatin, and BCNU (HD-CPB)
Study: 19747781
Drug: Intermediate-dose CPB
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose CPB (ID-CPB)
Study: 15929518
Drug: Sclerotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy plus octreotide (50 g/hr for 48 hours)
Study: 10202728
Drug: Non-preserved balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-preserved balanced salt solution
Study: 7604143
Drug: Progesterone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (mean daily dose of 1983 mg for 3 weeks)
Study: 155322
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) in combination with nitrosourea (streptozotocin)
Study: 155322
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) in combination with lactone (spironolactone)
Study: 155322
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) in combination with both nitrosourea and lactone
Study: 155322
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) in combination with nitrosourea (methyl CCNU)
Study: 155322
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) in combination with lactone (testolactone)
Study: 31840424
Drug: Advanced Routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced Routine (AR: Cleanser/Toner/Eye cream/Serum/Day & Night cream)
Study: 31840424
Drug: Simple Routine
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple Routine (SR: Cleanser & Day cream)
Study: 30721143
Drug: Fenugreek transdermal
Normalized name: FENUGREEK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek transdermal patch 10% (FDP)
Study: 30721143
Drug: Diclofenac dermal
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac dermal patch 1% (DP)
Study: 17254029
Drug: Local paint-PUVA
Normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local paint-PUVA using 0.1% 8-methoxypsoralen gel
Study: 15207885
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral 17beta-oestradiol (1 mg per day) combined with norgestimate (90 microg per day) for 3 consecutive days out of every 6-day treatment period (E2/iNGM)
Study: 7652500
Drug: Cefotaxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (2 g) plus Metronidazole (500 mg)
Study: 7652500
Drug: Imipenem/Cilastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/Cilastatin (1 g)
Study: 7652500
Drug: Meropenem (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (500 mg)
Study: 7652500
Drug: Imipenem/Cilastatin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/Cilastatin (500 mg)
Study: 7249528
Drug: Chlorpheniramine (H1-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (H1-receptor antagonist)
Study: 28456509
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g intravenous)
Study: 28456509
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g intravenous) within 3 hours of giving birth
Study: 25573527
Drug: Thalidomide (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (100-300 mg daily) plus dexamethasone (12 mg/m2 on days 1-4 of a 28-day cycle)